Laparoscopic trans-cystic-duct common-bile-duct exploration

One thousand seventy-one consecutive laparoscopic cholecystectomies were performed. Routine cholangiography was employed with a 99% success rate. One hundred thirty patients were found to have common duct stones (CBDS). In 48 (37%) patients they were unsuspected. One hundred eleven patients underwent attempted trans-cystic-duct extraction techniques (TCD-CBDE). One hundred three (93%) were successful. The following techniques were employed: 101—biliary endoscopy, 23—ampullary balloon dilation, 2—fluoroscopic basket retrieval.The average operative time was 136 min. The average postsurgical stay was 3.7 days. There were 19 (17%) complications—6 (5%) major. There were 4 retained stones (2 intentional) and 1 death. Patients over 65 years of age had more complications and patients with unsuspected CBDS under 65 years of age had the fewest.TCD-CBDE is a safe, effective way to extract common duct calculi. Endoscopy and basket stone retrieval was the primary technique employed.Presented at the annual meeting of the Society of American Gastrointestinal Endoscopic Surgeons (SAGES), Nashville, Tennessee, USA, 18–19 April 1994     

白细胞介素-13对肾小球系膜细胞增殖及细胞周期的影响

目的：探讨白细胞介素—13(IL—13)对肾小球系膜细胞(MC)增殖及其细胞周期的影响。方法：用甲基偶氮唑法(MTT)测定MC增殖，流式细胞术分析细胞周期。结果：IL—13在1ng／ml、5ng／ml、10ng／ml、100ng／ml浓度范围呈剂量依赖性抑制5％FCS培养的和脂多糖(LPS)诱导的MC增殖，抑制率分别为19．8％和29．23％、24．35％和37．05％、30．03％和46．6％、46．93％和55．23％。IL—13作用MC48h，使MC较多滞留于G1期，而S期细胞减少。结论：IL—13通过参与细胞周期的调控而抑制MC增殖。     

大剂量免疫化疗预防肾癌复发和转移的临床研究

目的 观察免疫化疗对肾癌远期复发及转移的预防作用。方法 肾癌根治术后患者18例。男13例，女5例。年龄37～78岁，平均56岁。分2组：①免疫化疗组13例。T1 1例，T2 8例，T3 4例。根治术后第10天起联合应用大剂量白细胞介素-2(远策欣，重组人白细胞介素-2，IL-2)和干扰素(远策素，重组人干扰素α2b，IFN-α)皮下注射以及5-氟脲嘧啶(5-Fu)静滴治疗。②对照组5例。T1 1例，T2 3例，T3 1例。均因为经济原因未行免疫化疗，仅行肾癌根治术。免疫治疗方法：IL-2800万U／次，皮下注射，每周3次，第1、4周；400万U／次，皮下注射，每周3次，第2、3周；IFN-α 600万U／次，皮下注射，每周3次，第2、3、6、7周；900万U／次，皮下注射，每周3次，第5、8周；用药后1h直肠应用消炎痛栓50mg。5-Fu1000～1250mg加入5％葡萄糖液500ml缓慢静滴(4～6h)，每周1次，第5～8周。2个月为1个治疗周期，间隔3个月可重复进行。治疗后每月检查血常规、肝肾功能、腹部B超、胸部及骨X线。结果 治疗组13例完成1～4个治疗周期，平均1．9个周期。未见严重毒副反应发生。随访60—87个月，12例无癌生存，1例术后43个月出现股骨转移，现行放疗，病灶稳定。对照组5例术后3—14个月发现远处转移，首发转移病灶：肺3例，肝1例，皮下1例。5例术后生存6～21个月，平均12．8个月。结论 以大剂量IL-2为主的免疫化疗方法安全，可有效地预防肾癌的远期复发和转移。     

哌拉西林/他佐巴坦治疗肾移植患者中重度肺部感染(附35例报告)

目的评价哌拉西林/他佐巴坦治疗肾移植患者中重度肺部感染的疗效与安全性。方法 对35例肾移植患者应用哌拉西林/他佐巴坦治疗中重度肺部感染的临床资料进行回顾性分析。结果 34例存活，1例死亡。哌拉西林/他佐巴坦治疗的有效率是91.43％，细菌清除率为92.59％，不良反应发生率为8.57％，主要是血肌酐轻度升高，但1周后逆转正常。结论 对于肾移植后的中重度肺部感染应给予高度重视和积极救治，及时给予有效的抗生素和联合治疗措施，调整免疫抑制方案和纠正低蛋白血症是治疗成功的关键。     

输尿管硬镜处理复杂肾结石残余结石

目的：提高复杂肾结石的治疗水平。方法：采用输尿管硬镜在术中从肾实质切口，术后从肾造接口取肾内残余结石。结果：5例手术中取石，4例取净；11例手术后取石，其中3例一次取石，5例二次取石，3例三次取石，7例取净。结论：复杂肾结石术中、术后配合输尿管硬镜取石可有效处理残余结石。     

移植肾组织TGF-β1和MMP-2表达及IV型胶原沉积与慢性移植肾肾病的关系

目的 探讨移植肾组织中转化生长因子β1(TGF-β1)和基质金属蛋白酶2(MMP-2)的表达及IV型胶原沉积与慢性移植肾肾病(CAN)的关系.方法 对18例CAN患者进行了移植肾切除术.光镜下观察切除的肾组织标本并根据其纤维化的程度进行分期,用免疫组织化学技术和图像分析法检测移植肾组织中TGF-β1和MMP-2表达量及IV型胶原沉积情况,并分析患者血肌酐(Cr)和尿素氮(BUN)的水平与移植肾纤维化程度的关系.结果 随着患者移植肾纤维化程度的加重,血清肌酐、尿素氮及肾组织中TGF-β1、IV型胶原基因表达量均增加,MMP-2表达量于移植肾纤维化早期明显升高,并随移植肾纤维化程度加重而逐渐降低.结论 移植肾组织中TGF-β1表达量增高及IV型胶原沉积可以促进CAN的进程,而MMP-2则可抑制其进展.     

“津血同源”“肾为唾”的研究

以23例肾功能不全与20例肾功正常患者的唾液尿素氮、钠、钾、舌面pH值和血液的相应生化检查作对照。结果唾液尿素氮、钾与血尿素氮、钾成正相关性。证实了中医“津血同源”“肾为唾”的理论。     

经皮腔内肾动脉成形术及自体肾移植治疗肾血管性高血压(附7例报告)

自1980到1986年,我院泌尿外科对4例单纯右侧肾动脉狭窄(RAS)性和3例双侧RAS性高血压病人进行了治疗。7例右侧 RAS皆进行了自体肾移植治疗,其中3例双侧RAS者采用PTA治疗,全部病人术后8天内血压皆恢复正常,随诊10个月到6年,无复发且都恢复工作。1例17岁女孩,术后2年结婚,又2年生一女孩,母女健在血压维持正常。     

一氧化氮合酶在肾脏缺血预处理中的表达

目的 :检测一氧化氮合酶 (NOS :eNOS ,iNOS ,nNOS)在肾脏缺血预处理动物模型肾组织中的表达 ,探讨NOS在肾脏缺血预处理中的可能作用机制。方法 :将 36只小白兔随机分为四组即对照组、缺血预处理组(IP)、缺血再灌注组 (I/R)和缺血预处理后再灌注组 (IP +I/R)。分别检测各组肾组织中NOS的表达及组织学变化。结果 :在急性肾缺血 6 0min再灌注 6 0min时 ,eNOS阳性表达在IP组和IP +I/R组明显高于I/R组和对照组 (P <0 .0 1) ,iNOS和nNOS在组织肾中未见明显表达。组织学变化发现I/R组肾组织中肾细胞发生明显变性坏死 ,而IP组和对照组未见明显改变。结论 :肾脏缺血预处理在肾脏缺血再灌注中具有保护作用 ,而NOS参与该作用机制。     

Assessment of split renal function with99mTc-aprotinin

The aim of this work is to correlate the net kidney uptake of^99mTc-aprotinin (TcA) in 103 subjects with separate effective renal plasma flow (ERPF) and some blood chemistry parameters at 90, 180, and 360 min postinjection both in the normal and diseased kidney. Correlations found with separate ERPFs are highly significant at any time (P < 0.001). However, although the slope of the regression line is steeper at 180 min,r tends to deteriorate slightly with time postinjection and a higher intercept on they axis: this pattern is more pronounced if diseased kidneys are considered separately. The following are probably related to the renal handling of TcA: (1) Early scans better reflect blood flow to the kidney, while later scans are more related to the metabolism/excretion tubular mechanisms; (2) correlations found with urea, creatinine, urea clearance, and creatinine clearance are highly significant at any time; (3) in 20 additional patients with diseased kidneys, renal uptake measurements done 360 min postinjection first with TcA and then with DMSA showed better correlations with ERPF employing TcA. Our results indicate that TcA is a feasible indicator of split renal function even at 90 min postinjection when a scan is easily carried out on an outpatient basis.This paper was in part presented at the European Nuclear Medicine Congress, August 14–17, 1984, Helsinki, Finland